BMO Capital Markets gave Halozyme (HALO 1.46%) an upgrade today, pushing the company's price target up from $4 to an incredible $12, which has shares up 15%. In the following video, Motley Fool health care analyst David Williamson takes us through BMO's thought process for an upgrade and Halozyme's upcoming catalysts.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.